1. Clinical Overview
Pramipexole is a non-ergoline dopamine agonist that selectively stimulates dopamine D2, D3, and D4 receptors. It is a first-line treatment for Parkinson's disease (PD) and is also approved for Restless Legs Syndrome (RLS). In the Indian context, it is widely used for managing motor symptoms of PD, often as monotherapy in early stages or as adjunctive therapy with levodopa in advanced stages to reduce 'off' time and levodopa-induced dyskinesias.
| Onset | Duration | Bioavailability |
|---|---|---|
| For PD: Therapeutic effect on motor symptoms begins within 1-2 hours of oral administration. For RLS: Onset of symptom relief typically occurs within 1-2 hours of the evening dose. | Approximately 8-12 hours, allowing for multiple daily dosing in PD. For RLS, a single evening dose provides coverage through the night. | >90% |
2. Mechanism of Action
Pramipexole exerts its therapeutic effects by directly stimulating postsynaptic dopamine receptors in the striatum, compensating for the dopamine deficiency characteristic of Parkinson's disease. Its high selectivity for D3 receptors (over D2) is thought to contribute to its efficacy and side effect profile.
3. Indications & Uses
- Idiopathic Parkinson's Disease (as monotherapy or adjunct to levodopa)
- Moderate-to-Severe Primary Restless Legs Syndrome (RLS)
4. Dosage & Administration
Adult Dosage: Parkinson's Disease: Start at 0.125 mg TID. Titrate weekly by 0.125 mg TID to effective dose (max 1.5 mg TID or 4.5 mg/day). Usual therapeutic range: 1.5-4.5 mg/day in divided doses. Restless Legs Syndrome: Start at 0.125 mg once daily, 2-3 hours before bedtime. Titrate every 4-7 days to 0.25 mg, then 0.5 mg if needed. Max dose for RLS: 0.5 mg daily.
Administration: Take with food to minimize nausea. Tablets should be swallowed whole with water. For PD, doses are typically taken 3 times daily. For RLS, take a single dose 2-3 hours before bedtime. Do not crush or chew. If a dose is missed, take the next dose at the regular time; do not double dose. Taper gradually when discontinuing (reduce by 0.75 mg per day until 1.5 mg/day, then reduce by 0.375 mg per day) to avoid withdrawal symptoms or neuroleptic malignant syndrome-like events.
5. Side Effects
Common side effects may include:
- Nausea
- Dizziness
- Somnolence (daytime sleepiness)
- Insomnia
- Constipation
- Peripheral edema
- Headache
- Fatigue
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Levodopa/Carbidopa | Increased dopaminergic effects (improved motor control) but also increased risk of dyskinesias, hallucinations, and orthostatic hypotension. | Major |
| Antipsychotics (e.g., Haloperidol, Risperidone, Olanzapine) | Antagonism of dopamine receptors, reducing efficacy of pramipexole. May worsen psychosis. | Major |
| Metoclopramide, Domperidone | Domperidone (peripheral antagonist) may be used. Metoclopramide (central antagonist) will antagonize pramipexole's effects. | Major |
| Antihypertensives | Additive hypotensive effects, increasing risk of orthostasis and syncope. | Moderate |
| CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive sedation, somnolence, and risk of sudden sleep attacks. | Major |
| Cimetidine | Reduces renal tubular secretion of pramipexole, increasing AUC by ~50%. Dose adjustment may be needed. | Moderate |
| Other Dopamine Agonists (e.g., Ropinirole, Rotigotine) | Additive effects and side effects; not recommended. | Major |
7. Patient Counselling
- DO take with food to reduce stomach upset.
- DO report any new or increased urges (gambling, shopping, eating, sexual thoughts) to your doctor immediately.
- DO rise slowly from sitting/lying position to avoid dizziness.
- DO NOT stop taking this medicine suddenly. Always taper under doctor's guidance.
- DO NOT drive or operate heavy machinery until you know how this medicine affects you, especially regarding sleepiness.
- DO NOT drink alcohol while on this medication.
8. Toxicology & Storage
Overdose: Symptoms are an extension of pharmacodynamic effects: severe nausea, vomiting, hypotension, agitation, hallucinations, involuntary movements (dyskinesia), and profound somnolence progressing to coma. Cardiac arrhythmias have been reported.
Storage: Store below 30°C. Protect from light and moisture. Keep in the original blister pack or container. Keep out of reach of children. Do not use after the expiry date printed on the pack.